Pyxis Oncology (PYXS) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rocket Pharmaceuticals (RCKT) has outperformed Pyxis Oncology (PYXS) over the past year, losing 33.4% versus a loss of 62.3%. Over five years, PYXS leads with a -85.9% price change compared with -91.8% for RCKT. Rocket Pharmaceuticals is the larger company by market cap ($217.7 million vs $216.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PYXS | RCKT |
|---|---|---|
| Share price | $1.81 | $1.95 |
| Market cap | $216.49M | $217.74M |
| 1-day change | +7.74% | -7.58% |
| YTD return | +57.39% | -44.44% |
| 1-year return | -62.29% | -33.45% |
| 5-year return | -85.90% | -91.76% |
| EPS (TTM) | $-1.27 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.86M | $0 |
| Revenue growth (YoY) | -14.17% | — |
| Net income (latest FY) | $-79.62M | $-223.12M |
| Gross margin | 82.77% | — |
| Operating margin | -609.18% | — |
| Net margin | -574.55% | — |
| 52-week high | $5.55 | $5.45 |
| 52-week low | $1.03 | $1.94 |
| Distance from 52-week high | -67.39% | -64.22% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +354.14% | +326.15% |
| Average volume | 1.06M | 1.90M |
| Shares outstanding | 119.61M | 111.66M |
| Employees | 56 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCKT has outperformed PYXS by 28.8 percentage points over the past year.
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
PYXS vs RCKT FAQ
Which is bigger, Pyxis Oncology or Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $217.74M compared with $216.49M for Pyxis Oncology (PYXS).
Which stock has performed better over the past year, PYXS or RCKT?
RCKT returned -33.45% over the past 12 months, compared with -62.29% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are Pyxis Oncology and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.